Next Article in Journal
Carbazole- and Triphenylamine-Substituted Pyrimidines: Synthesis and Photophysical Properties
Previous Article in Journal
New Quinolone-Based Thiosemicarbazones Showing Activity Against Plasmodium falciparum and Mycobacterium tuberculosis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 24
Issue 9
10.3390/molecules24091741
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

New Series of Thiazole Derivatives: Synthesis, Structural Elucidation, Antimicrobial Activity, Molecular Modeling and MOE Docking

by
Ismail Althagafi
1,*,
Nashwa El-Metwaly
1,2 and
Thoraya A. Farghaly
1,3,*
1
Chemistry Department, Faculty of Applied Science, Umm Al-Qura University, Makkah 21514, Saudi Arabia
2
Chemistry Department, Faculty of Science, Mansoura University, Mansoura 002050, Egypt
3
Chemistry Department, Faculty of Science, Cairo University, Giza 12613, Egypt
*
Authors to whom correspondence should be addressed.
Molecules 2019, 24(9), 1741; https://doi.org/10.3390/molecules24091741
Submission received: 3 April 2019 / Revised: 30 April 2019 / Accepted: 2 May 2019 / Published: 4 May 2019
Browse Figures
Versions Notes

Abstract

:
Based on the extensive biological activities of thiazole derivatives against different types of diseases, we are interested in the effective part of many natural compounds, so we synthesized a new series of compounds containing di-, tri- and tetrathiazole moieties. The formation of such derivatives proceeded via reaction of 2-bromo-1-(4-methyl-2-(methylamino)thiazol-5-yl)ethan-1-one with heterocyclic amines, o-aminothiophenol and thiosemicarbazone derivatives. The structure and mechanistic pathways for all products were discussed and proved based on spectral results, in addition to conformational studies. Our aim after the synthesis is to investigate their antimicrobial activity against various types of bacteria and fungi species. Preceeding such an investigation, a molecular docking study was carried out with selected conformers, as representative examples, against three pathogen-proteins. This preliminary stage could support the biological application. The potency of these compounds as antimicrobial agents has been evaluated. The results showed that derivatives which have di- and trithiazole rings displayed high activity that exceeds the used standard antibiotic.

Graphical Abstract

1. Introduction

It is not coincidental that the first effective antibiotics used to treat microbes (the penicillins, Figure 1) contains a thiazole ring. Also, several commercial drugs for various types of diseases that contain thiazole moieties, were synthesized, as illustrated in Figure 1. Thiazole derivatives are actually a considerable group of heterocyclic compound that have therapeutic effects against several diseases [1,2]. The most pertinent and modern studies have manifested that these molecules display antifungal [3], antibacterial [4], anti-inflammatory [5,6], analgesic [7], and anti-cancer [8,9] activities. Many patents have been registered for thiazole compounds with antimicrobial activity [10,11]. It has been demonstrated that the design and synthesis of organic compounds containing more than one thiazole ring unit enhanced their therapeutic activities [12,13,14,15]. Thus, many researchers have become interested in the synthesis of molecules containing more than one thiazole moiety [16,17]. Also, as a result of persistent microbial resistance to antibiotics, chemical and pharmaceutical researchers are constantly seeking to discover and synthesize alternatives to known antibiotics. Thus, from viewpoint of the promising antimicrobial activity of thiazoles and in continuation to our efforts concerning the synthesis of bioactive heterocyclic compounds [18,19,20,21,22,23,24], herein, we aimed to synthesize a new series of compounds having more than one thiazole ring. This was executed via the reaction of 2-bromo-1-(4-methyl-2-(methylamino)thiazol-5-yl)ethan-1-one with different heterocyclic amines and thiosemicarbazones. Due to the possibility of formation of more than one isomer from the reaction of heterocyclic amines with the phenacyl bromide derivative, we aimed to elucidate the actual structural forms through various techniques. Moreover, the antimicrobial activity of the products was screened against different types of bacteria and fungi and simulated by docking processes for some chosen conformers.

2. Results and Discussion

2.1. Chemistry

The starting material required in this study was 2-bromo-1-(4-methyl-2-(methylamino)thiazol-5-yl)ethan-1-one (2), which was prepared through bromination of 5-acetyl-4-methyl-2-(methylamino)thiazole (1) in acidic medium, as previously reported [25] (Scheme 1). The phenacyl bromide derivative 2 was reacted with a mole equivalent of 2-aminothiazole (3) in ethanol under reflux to give one of two possible isomers 6A or 6B as indicated by the presence of only one spot in TLC. The spectral data (IR, MS) and elemental analysis cannot distinguish the actual product among the suggested possibilities. 1H-NMR of the isolated product showed a remarkable singlet at δ = 8.20 ppm for the imidazole proton. The high value of such a chemical shift indicated that this =CH is adjacent to a sp3 hybridized nitrogen atom [26,27], which is possible in isomer 6A rather than isomer 6B. As illustrated in Scheme 2, the reaction proceeds via the formation of an iminothiadiazole intermediate I, followed by in-situ dehydrative cyclization to form the desired fused heterocycle 6A [19]. Dalimba et al., also proved this route using X-ray crystallographic analysis, that indicated the elimination of HBr from the endo-NH group, while, the exocyclic-NH group condensed with a carbonyl group to lose H2O [27]. 2-Aminobenzothiazole (4) reacted in a similar way with compound 2 to afford 5-(benzo[d]imidazo [2,1-b]thiazol-2-yl)-N,4-dimethylthiazol-2-amine (7A). The other possible isomer 7B (Scheme 1), was discarded based on 1H-NMR data and a conformational study, that will discussed later. As for instance, the 1H-NMR spectrum of the isolated product showed a characteristic singlet signal at δ = 8.76 ppm for the imidazole-H proton of isomer 7A. 5-(4H-Benzo[b][1,4]thiazin-3-yl)-N,4-dimethylthiazol-2-amine (8A) was formed via reaction of 2-aminothiophenol with 2-bromo-1-(4-methyl-2-(methylamino)thiazol-5-yl)ethan-1-one (2) in ethanol under reflux (Scheme 1). The formation of isomer 8A instead of 8B agrees with the fact that the nucleophilicity of the sulfur atom is more than that of the NH2 group thus, the reaction started with S-alkylation with the elimination of HBr, followed by concurrent removal of a water molecule from NH2 and the carbonyl group. Moreover, the mass spectra of new derivatives 6, 7 and 8 displayed the correct molecular ions as suggested for their molecular formulae (see Experimental part). Furthermore, the IR spectra for all derivatives 6–8 were free from any absorption bands characteristic for C=O, but, revealed the presence of two characteristic bands for NH and C=N at 3417-3238 and 1634-1612 cm−1, respectively.
Other heterocyclic amines namely, 5-aminotetrazole 9, 2-aminobenzimidazole 10, and 3-amino-1,2,4-triazole 11 reacted with compound 2 to give new series of thiazole rings carrying different azoles at position 5, indicated by numbers 12–14, respectively (Scheme 3). In this case, none of the spectral data (MS, IR and NMR) can discriminate between the two possible isomers 12A and 12B, while the structural modeling study can do that. For instance, its IR-data are in agreement with the two suggested structures 12A and 12B, which are free from any C=O absorption bands and have notable bands for NH and C=N groups.
Based on the high reactivity of α-bromoketone derivative 2, it was further reacted with pyrimidine thiones 15a,b in dioxane in the presence of a catalytic amount of Et3N to afford one of three isomers 17A, 17B or 17C (Scheme 4). The preliminary choice for the actual product of reaction, was based on the 13C-NMR spectrum, that revealed the presence of a remarkable signal for the C=O group carbon at δ 166.7 ppm, a value that indicated that the carbonyl group was adjacent to a sp3 nitrogen atom [28] as in the two isomers 17A and 17C. The IR of the product 17a (R = Ph), displayed significant bands at, ύ = 3430 (NH) and 1653 (C=O), which suggested the presence of 17A tautomer in the solid state, while, the 1H-NMR spectrum suggested the existence of 17C tautomer, through the appearance of a singlet signal for the CH2 group at δ = 4.44 ppm and lack of from any signals for a NH group (Figure 2), while the other derivative 17b (R = CH3) exists in only the tautomeric form 17A as proved from its spectral data (see Experimental part). The formation of products 17a,b started with substitution reactions through the formation of intermediate 16, which was followed by concurrent elimination of a water molecule (Scheme 4).
The simple and easy synthesis of more than one thiazole ring in molecules was achieved by the reaction of thiasemicarbazone derivatives 18a–f, 20a,b, 22 and 23 with α-bromoketone derivative 2 (Scheme 5, Scheme 6 and Scheme 7). Such reactions were carried out in dioxane in the presence of triethylamine to give thiazole derivatives 19a–f, 21a,b, 24 and 25. The structure of all these compounds has been verified through their spectral data, elemental analysis and conformational analysis. Figure 3 shows the fragmentation pattern for product 19b. 1H NMR of compound 24 revealed all remarkable signals for aliphatic, aromatic and three NH protons as shown in the Experimental section. Moreover, the data from their IR spectra, which revealed the disappearance of C=O absorption bands and the existence of NH and C=N groups, proved the formation of these compounds 19a–f, 21a,b, 24 and 25.

2.2. Conformational Study

All synthesized conformers as well as tautomers, were structurally investigated (Figure S1), to confirm the proposed reaction mechanism. The reaction mechanism was already established mainly based on spectroscopic tools. The comparative view for conformer couples such as 6A and 6B; 7A and 7B; 8A and 8B; 12A and 12B; 17A and 17B, may confirm all reactions-pathways. The best discrimination among each couple confirms the mechanisms proposed in all the synthesis schemes. Firstly, their formation energies (Table 1) point to their relative stability, which controls the reaction trends. As we know, the less the energy of formation (E, a. u.), the more stable the conformer. This appeared excellently for tautomers A not B. Secondly, the recorded energy gaps (∆E = ELUMO − EHOMO), reflect the comparative stability that is consistent with the suggested conformers (A compounds). With respect to tautomers 3A and 3B, we considered the reaction-determining step of Scheme 2, and a remarkable stability was recorded for the 3A tautomer. Also, regarding the two tautomers, the charge on the N(6) atom was −0.51307 or −0.338355, respectively. The two values indicate the highly nucleophilic nature of the nitrogen atom in compound 3A. This agrees excellently with the previously suggested reaction pathway. Another additional proof was obtained from their electrostatic maps (Figure 4), which exhibited a broad electron cloud over 3A (−6.935 × 10−2) but not the 3B tautomer (−5.868 × 10−2). Such an observation suggests the superiority of 3A tautomer over the 3B one. Regarding intermediate 16, the one in the reaction pathway in Scheme 4, its electrostatic map displays a broad electron cloud (−7.182 × 10−2) over the whole molecule. Also, the charge on N(18) (which is adjacent to the carbonyl group) was −0.782807, while the charge on N (14) was −0.580283, which points to the high nucleophilicity of the N(18) atom, which was already proposed in the reaction mechanism.
HOMO and LUMO frontier images were extracted and displayed (Figures S2 and S3). The HOMO mainly appeared distributed over the whole molecule in a good way, especially for the A conformers, while, the LUMO mainly appeared condensed in a defined part in the compound. This is somewhat logical, that the two orbitals consider the counterparts in the compounds. Essential physical parameters were calculated for all optimized conformers, to gain some insight into their general characteristics. Electronegativity (χ), chemical potential (μ), global hardness (η), global softness (S), global electrophilicity index (ω) and absolute softness (σ), were the calculated parameters (Table 1). The differentiation between all tested compounds allows us to make the following remarks; (i) the values of electrophilicity index (ω), reflect significant toxicity for most of the tested compounds, especially of 19, 21, 24 and 25. (ii) The global hardness (η) and absolute softness (σ) values, clarify the high degree of softness for compounds 13, 19, 21 and 24 [29,30,31,32], which should led to different biological activity.

2.3. Molecular Docking Study

This study aimed to provide a good simulation of what happens inside infected cells after treatment with the suggested inhibitors. Implementing the MOE module, the docking process was executed between 14, 17a, 19f and 24 conformers and 3k4p, 1ydo and 1ecl PDB co-crystals of Aspergillus niger, Bacillis subtilis and Escherichia coli, respectively [33]. Fundamental data was exported (Table 2) and docking complexes images (interaction and surface maps), are presented as well in Figure 5 and Figure S4. Table 2 includes ligand types (centers of H- interaction), and protein receptors which interact with the ligands. Types of binding inside complexes, the length of H- bonding as well as energies calculated for docking complexes are also included.
The underlying mechanism of action was suggested by all docking processes, which varied from the best interaction to others with moderate binding, based on the following remarks;. (i) The energy value scores (S) appear in the −5.8156 to −7.0064 and −4.3294 to −5.3916 ranges, which represent the best to moderate interactions, respectively. (ii) The ligation mode was mainly focused on, S, N, 5-ring and 6-ring sites. (iii) The main binding receptor-backbones were lysine, asparagine, glutamate, alanine, serine and tryptophan. (iv) The interactions appeared to covering all possible types, such as π-H, π-π, H-donor and H-acceptor. (v) From all the previous remarks the best inhibition may be expected for 17a, 24 and 19f against the 1ydo protein of Bacillis subtilis bacteria [34,35]. The displayed images of docking complexes (Figure 5 and Figure S3), especially with the interacting image (A), clarify the formerly concluded data. Regarding the surface maps (B images), which were built over line dummies without isolating the receptor atoms, they lead to a good view of the electrostatic interactions inside the docking complexes. Good inhibition is concluded with some conformers, which exhibit high occupancy of the inside surface grooves that point to a best blocking of amino acid active sites.

2.4. Biological Activity

Antimicrobial Activity

The antimicrobial activity was assayed for the starting α-bromoketone derivative 2 and the seventeen synthetic derivatives 6–8, 12–14, 17a,b, 19a, 19c–f, 21a,b, 24, and 25 against two fungal species, and four Gram-positive as well as four Gram-negative bacteria, as illustrated in Table 3. The activity was reported by measuring the diameter of the inhibition zone (IZD) in mm ± standard deviation. While determining the antimicrobial activity, amphotericin B, ampicillin, and gentamicin were used as reference compounds for fungi, Gram-positive bacteria, and Gram-negative bacteria, respectively.
It is easy to note that the starting α-bromoketone derivative 2 showed less activity than the the used antifungal and antibacterial standards against most of the tested fungi and bacteria. The activity of the thiazole ring was affected by the conversion of the α-bromoketone group to heterocyclic rings at position 5. The presence of an imidazotetrazole ring at position-5 of the thiazole ring, enhanced the activity of compound 12 (IZ = 23.3 µg/mL) to a level similar to that of amphotercin B against Aspergillus niger, whereas, upon insertion of imidazotriazole, thiazolopyrimidine, thiazole rings in the same position-5, a favorable activity was recorded for compounds 14, 17a, 19a, 19c–f, 21a and 24 that exhibited higher activity than the standard drug toward Aspergillus niger (Table 4, Table 5 and Table 6). Investigating the product activity results recorded against Gram positive bacteria (Staphylococcus aureus), three derivatives 14, 19a and 21a are more potent than the reference drug (ampicillin), but only derivative 14 exceed the activity of the standard against Staphylococcus epidermidis. Observing Gram negative bacteria, six derivatives 17a,b, 19a,e,f, 24 are more potent than the reference drug, as depicted in Table 4, Table 5 and Table 6. In contrast to these results, we found that none of the investigated derivatives showed aany activity against Gram-positive Streptococcus pyogenes and Gram-negative Pseudomonas aeruginosa.
Table 7 presents the minimum inhibition concentration (MIC) values for some selected examples 7, 13, 17a,b, 19c, and 21b that showed significant inhibition zones. The results revealed that most of these compounds displayed promising activity against Aspergillus niger, whereas, only compound 17a showed MIC similar to Amphotericin B against Geotricum candidum. Focusing on the results of G (+) bacteria and G (−) bacteria, the most active derivative is 17a. Moreover, compounds 7 and 13 showed high reactivity toward the bacterium Salmonella typhimurium (MIC = 0.49 μg/mL). Finally, from the inhibition zone and MIC investigations of the tested compounds, we found that the insertion of a heterocyclic system at position-5 of the thiazole ring, improved the antimicrobial activity. Also, with the presence of more than one thiazole ring in the system, promising activity concluded to be more than that of the reference antibiotics used was observed.

3. Experimental Section

3.1. General Experimental Procedures

All melting points were measured on a Electrothermal IA 9000 series digital melting point apparatus (Bibby Scientific Limited. Beacon Road, Stone, Staffordshire, UK). IR spectral analyses were recorded on a FT-IR-4100 spectrophotometer (400–4000 cm−1, JASCO, Easton, MD 21601, United States). 1H and 13C-NMR spectral analysis were obtained on a Bruker 400 MHz instrument (JEOL, Tokyo, Japan). Mass spectral analysis was obtained at 70 eV on Shimadzu GCMS-QP 1000 EX mass spectrometer (Tokyo, Japan) at a heating rate 40 °C/min. The elemental analysis was carried out using a 2400 CHN Elemental Analyzer (Perkin-Elmer, Inc. 940 Winter Street Waltham, MA, USA) instrument. The biological evaluation of the products was carried out at the Regional Center of Mycology and Biotechnology, Al-Azhar University, Cairo, Egypt. Theoretical calculations were performed using Gaussian 09 and AutoDock Tools 4.2. 2-Bromo-1-(4-methyl-2-(methylamino)thiazol-5-yl)ethan-1-one (2) was synthesized as previously reported [25].

3.2. Reaction of Heterocyclic Amines 3, 4, 9–11 and 2-Aminothioplenol (5) with 2-Bromo-1-(4-methyl-2-(methylamino)thiazol-5-yl)ethan-1-one (2)

A mixture of equimolar quantities of 2-bromo-1-(4-methyl-2-(methylamino)thiazol-5-yl)ethan-1-one (2, 1.25 gm, 5 mmol) and heterocyclic amines 3, 4, 9–11 or 2-aminothioplenol 5 (5 mmol) in ethanol (30 mL) was refluxed for 10 h (the progress of the reactions was monitored by TLC). After the reaction was complete, the reaction mixture was filtered, the filtrate washed with methanol, and crystallized from a suitable solvent to give derivatives 6, 7, 12–14 and 8, respectively.

3.2.1. 5-(Imidazo[2,1-b]thiazol-6-yl)-N,4-dimethylthiazol-2-amine (6)

Yellow solid, (78% yield), mp 243–244 °C; (EtOH); IR (KBr) νmax 3417 (NH), 3038 (sp2 C-H), 2997 (sp3 C-H), 1634 (C=N) cm−1; 1H-NMR (DMSO-d6) δ 2.45 (s, 3H, CH3), 3.56 (s, 3H, CH3), 7.37 (d, J = 3.6 Hz, 1H, thiazole-H), 7.94 (d, J = 3.6 Hz, 1H, thiazole-H), 8.20 (s, 1H, imidazole-H), 9.60 (s, 1H, NH); MS m/z (%) 250 (M+, 26), 239 (53), 234 (47), 224 (89), 220 (16), 206 (62), 191 (45), 188 (57), 183 (100), 150 (30), 119 (34), 91 (33), 65 (42), 48 (54). Anal. Calcd. for C10H10N4S2 (250.34): C, 47.98; H, 4.03; N, 22.38. Found: C, 48.05; H, 3.89; N, 22.24%.

3.2.2. 5-(Benzo[d]imidazo[2,1-b]thiazol-2-yl)-N,4-dimethylthiazol-2-amine (7)

Yellow solid, (83% yield), mp 265–266 °C; (EtOH); IR (KBr) νmax 3238 (NH), 3047 (sp2 C-H), 2987 (sp3 C-H), 1623 (C=N) cm−1; 1H-NMR (DMSO-d6) δ 2.59 (s, 3H, CH3), 3.56 (s, 3H, CH3), 7.40 (t, J = 7 Hz, 1H, Ar-H), 7.54 (t, J = 7 Hz, 1H, Ar-H), 8.01 (d, J = 7.7 Hz, 1H, Ar-H), 8.09 (d, J = 7.7 Hz, 1H, Ar-H), 8.76 (s, 1H, imidazole-H), 9.62 (s, 1H, NH); MS m/z (%) 300 (M+, 34), 285 (22), 270 (29), 254 (40), 175 (26), 153 (27), 147 (23), 150 (28), 138 (71), 129 (29), 77 (17). Anal. Calcd. for C14H12N4S2 (300.40): C, 55.98; H, 4.03; N, 18.65. Found: C, 55.87; H, 3.87; N, 18.58%.

3.2.3. 5-(4H-Benzo[b][1,4]thiazin-3-yl)-N,4-dimethylthiazol-2-amine (8)

Yellow solid, (88% yield), mp 110–112 °C; (EtOH/Dioxane); IR (KBr) νmax 3374, 3293 (2NH), 3059 (sp2 C-H), 2926 (sp3 C-H), 1612 (C=N) cm−1; 1H-NMR (DMSO-d6) δ 2.51 (s, 3H, CH3), 2.89 (s, 3H, CH3), 5.45 (s, 1H, benzothiazine-H), 6.42 (t, J = 7 Hz, 1H, Ar-H), 6.73 (d, J = 7 Hz, 1H, Ar-H), 7.01 (d, J = 7 Hz, 1H, Ar-H), 7.07 (t, J = 7 Hz, 1H, Ar-H), 7.4 (s, 1H, NH), 9.07 (s, 1H, NH); MS m/z (%) 275 (M+, 13), 272 (100), 256 (7), 166 (10), 154 (3), 152 (17), 147 (4), 139 (86), 127 (7), 113 (37), 102 (23), 91 (31), 83 (72), 76 (17). Anal. Calcd. for C13H13N3S2 (275.39): C, 56.70; H, 4.76; N, 15.26. Found: C, 56.85; H, 4.58; N, 15.17%.

3.2.4. 5-(4H-Imidazo[1,2-d]tetrazol-5-yl)-N,4-dimethylthiazol-2-amine (12)

Yellow solid, (76% yield), mp 155–157 °C; (EtOH); IR (KBr) νmax 3428, 3203 (2NH), 3106, 2924 (sp3 C-H), 1646, 1599 (C=N) cm−1; 1H-NMR (DMSO-d6) δ 2.51 (s, 3H, CH3), 2.89 (s, 3H, CH3), 6.92 (s, 1H, NH), 7.03 (s, 1H, NH), 8.85 (s, 1H, imidazole-H); MS m/z (%) 235 (M+, 25), 220 (16), 210 (55), 192 (24), 191 (33), 189 (38), 170 (23), 123 (32), 106 (24), 103 (26), 96 (34), 82 (20), 64 (100). Anal. Calcd. for C8H9N7S (235.27): C, 40.84; H, 3.86; N, 41.68. Found: C, 41.10; H, 3.65; N, 41.59%.

3.2.5. 5-(1H-Benzo[d]imidazo[1,2-a]imidazol-2-yl)-N,4-dimethylthiazol-2-amine (13)

Yellow solid, (65% yield), mp 140–142 °C; (EtOH/Dioxane); IR (KBr) νmax 3438, 3165 (2NH), 3094 (sp2 C-H), 2991 (sp3 C-H), 1649 (C=N) cm−1; 1H-NMR (DMSO-d6) δ 2.25 (s, 3H, CH3), 2.85 (s, 3H, CH3), 7.12 (d, J = 7 Hz, 1H, Ar-H), 7.24 (d, J = 7 Hz, 1H, Ar-H), 8.0–8.21 (m, 2H, Ar-H), 8.29 (s, 1H, imidazole-H), 10.44 (s, 1H, NH), 10.58 (s, 1H, NH); MS m/z (%) 283 (M+, 22), 264 (41), 245 (56), 238 (17), 230 (49), 207 (100), 181 (66), 167 (41), 137 (83), 124 (22), 115 (42), 98 (62), 67 (45). Anal. Calcd. for C14H13N5S (283.35): C, 59.34; H, 4.62; N, 24.72. Found: C, 59.17; H, 4.55; N, 24.60%.

3.2.6. 5-(4H-Imidazo[1,2-b][1,2,4]triazol-5-yl)-N,4-dimethylthiazol-2-amine (14)

Yellow crystals, (91% yield), mp 245–146 °C; (EtOH); IR (KBr) νmax 3436, 3124(2NH), 2978 (sp3 C-H), 1629 (C=N) cm−1; 1H-NMR (DMSO-d6) δ 2.41 (s, 3H, CH3), 3.03 (s, 3H, CH3), 6.75 (s, 1H, NH), 6.85 (s, 1H, NH), 9.55 (s, 2H, 2C-H); MS m/z (%) 234 (M+, 21), 224 (7), 221 (15), 187 (5), 166 (12), 153 (5), 145 (25), 127 (14), 118 (28), 107 (4), 84 (11), 73 (28), 67 (6), 65 (54), 63 (100). Anal. Calcd. for C9H10N6S (234.28): C, 46.14; H, 4.30; N, 35.87. Found: C, 46.25; H, 4.29; N, 35.75%.

3.3. Reaction of 2-Bromo-1-(4-methyl-2-(methylamino)thiazol-5-yl)ethan-1-one (2) with Pyrimidinethione Derivatives 15a,b and thiosemicarbazones 18a–f, 20a,b 22, or 23

To a stirred hot solution of pyrimidinethione derivatives 15a or 15b or thiosemicarbazone derivatives 18a–f, 20a,b 22, or 23 (5 mmole) in dioxane (30 mL) was added 2-bromo-1-(4-methyl-2-(methylamino)thiazol-5-yl)ethan-1-one (2, 1.25 g, 5 mmol) and triethylamine (0.7 mL) then the reaction mixture was refluxed for 6 h. After cooling, the formed solid product was collected by filtration and washed with aqueous ethanol to dissolve any triethylamine hydrochloride crystals, dried and crystallized from ethanol/dioxane to give thiazolopyrimidines 17a,b or hydrazine-thiazole derivatives 19a–f, 21a,b, 24 and 25.

3.3.1. 3-(4-Methyl-2-(methylamino)thiazol-5-yl)-7-phenyl-5H-thiazolo[3,2-a]pyrimidin-5-one (17a)

Yellow solid, (81% yield), mp 200–201 °C; IR (KBr) νmax 3430 (NH), 2926 (sp3 C-H), 1653 (C=O), 1564 (C=N) cm−1; 1H-NMR (DMSO-d6) δ 2.51 (s, 3H, CH3), 3.30 (s, 3H, CH3), 4.44 (s, 2H, CH2), 6.69 (s, 1H, pyrimidine-H), 7.36–7.95 (m, 5H, Ar-H); 13C-NMR (DMSO-d6) δ 18.9 (CH3), 30.1 (CH2), 34.0 (N-CH3), 110.9, 112.0, 114.3, 119.8, 125.5, 127.32, 129.6, 131.9, 132.6, 145.7, 147.6, 166.7 (C=O) ppm; MS m/z (%) 354 (M+, 40), 338 (28), 331 (40), 327 (30), 311 (41), 269 (44), 258 (69), 201 (30), 173 (43), 155 (56), 111 (83), 86 (47), 60 (100). Anal. Calcd. for C17H14N4OS2 (354.45): C, 57.61; H, 3.98; N, 15.81. Found: C, 57.73; H, 3.76; N, 15.72%.

3.3.2. 7-Methyl-3-(4-methyl-2-(methylamino)thiazol-5-yl)-5H-thiazolo[3,2-a]pyrimidin-5-one (17b)

Dark orange solid, (92% yield), mp 259–260 °C; IR (KBr) νmax 3430 (NH), 2928 (sp3 C-H), 1636 (C=O), 1560 (C=N) cm−1; 1H-NMR (DMSO-d6) δ 2.07 (s, 3H, CH3), 2.51 (s, 3H, CH3), 3.37 (s, 3H, CH3), 5.68 (s, 2H, pyrimidine-H and thiazole-H), 12.24 (s, 1H, NH). MS m/z (%) 292 (M+, 100), 284 (59), 277 (23), 265 (21), 256 (63), 246 (32), 231 (25), 202 (44), 163 (25), 139 (16), 127 (40), 108 (53), 87 (35), 82 (25). Anal. Calcd. for C12H12N4OS2 (292.38): C, 49.30; H, 4.14; N, 19.16. Found: C, 49.45; H, 4.05; N, 19.02%.

3.3.3. N,4′-dimethyl-2-(2-(1-phenylethylidene)hydrazineyl)-[4,5′-bithiazol]-2′-amine (19a)

Green solid, (77% yield), mp 235–237 °C; IR (KBr) νmax br. 3419 (2NH), 2929 (sp3 C-H), 1554 (C=N) cm−1; 1H-NMR (DMSO-d6) δ 2.31 (s, 3H, CH3), 2.51 (s, 3H, CH3), 2.89 (s, 3H, CH3), 7.39–8.27 (m, 7H, Ar-H, thiazole-H, NH), 10.22 (s, 1H, NH); MS m/z (%) 343 (M+, 14), 334 (14), 303 (17), 282 (30), 218 (20), 163 (10), 127 (100), 93 (61), 91 (49), 85 (12). Anal. Calcd. for C16H17N5S2 (343.47): C, 55.95; H, 4.99; N, 20.39. Found: C, 56.14; H, 4.80; N, 20.27%.

3.3.4. 2-(2-(1-(4-Chlorophenyl)ethylidene)hydrazineyl)-N,4′-dimethyl-[4,5′-bithiazol]-2′-amine (19b)

Green solid, (68% yield), mp 226–228 °C; IR (KBr) νmax br. 3423 (2NH), 2925 (sp3 C-H),1552 (C=N) cm−1; 1H-NMR (DMSO-d6) δ 2.29 (s, 3H, CH3), 2.33 (s, 3H, CH3), 3.37 (s, 3H, CH3), 7.42–7.98 (m, 6H, Ar-H, thiazole-H, NH), 10.26 (s, 1H, NH); MS m/z (%) 379 (M++2, 12), 378 (M++1, 4), 377 (M+, 38), 364 (28), 346 (25), 337 (34), 328 (100), 265 (50), 251 (49), 239 (43), 225 (22), 216 (30), 188 (49), 128 (52), 83 (53). Anal. Calcd. for C16H16ClN5S2 (377.91): C, 50.85; H, 4.27; N, 18.53. Found: C, 51.02; H, 4.13; N, 18.44%.

3.3.5. 2-(2-(1-(4-Bromophenyl)ethylidene)hydrazineyl)-N,4′-dimethyl-[4,5′-bithiazol]-2′-amine (19c)

Green solid, (64% yield), mp 220–222 °C; IR (KBr) νmax br. 3416 (2NH), 2919 (sp3 C-H), 1552 cm-1; 1H-NMR (DMSO-d6) δ 2.28 (s, 3H, CH3), 2.33 (s, 3H, CH3), 3.36 (s, 3H, CH3), 7.56–7.92 (m, 5H, Ar-H, thiazole-H), 8.31 (s, 1H, NH), 10.26 (s, 1H, NH); MS m/z (%) 422 (M+, 25), 406 (52), 390 (100), 371 (56), 347 (32), 325 (37), 302 (38), 270 (67), 238 (36), 111 (24), 72 (20). Anal. Calcd. for C16H16BrN5S2 (422.36): C, 45.50; H, 3.82; N, 16.58. Found: C, 45.75; H, 3.68; N, 16.46%.

3.3.6. 2-(2-(1-(4-Fluorophenyl)ethylidene)hydrazineyl)-N,4′-dimethyl-[4,5′-bithiazol]-2′-amine (19d)

Green solid, (72% yield), mp 249–250 °C; IR (KBr) νmax 3423, 3249 (2NH), 3161, 2936 (sp3 C-H), 1602, 1560 (C=N) cm−1; 1H-NMR (DMSO-d6) δ 2.28 (s, 3H, CH3), 2.51 (s, 3H, CH3), 3.51 (s, 3H, CH3), 7.17–8.00 (m, 5H, Ar-H, thiazole-H), 8.24 (s, 1H, NH), 10.19 (s, 1H, NH); MS m/z (%) 361 (M+, 12), 338 (22), 299 (66), 273 (45), 271 (100), 252 (16), 202 (16), 189 (15), 136 (39). Anal. Calcd. for C16H16FN5S2 (361.46): C, 53.17; H, 4.46; N, 19.38. Found: C, 53.24; H, 4.31; N, 19.29%.

3.3.7. N,4′-Dimethyl-2-(2-(1-(p-tolyl)ethylidene)hydrazineyl)-[4,5′-bithiazol]-2′-amine (19e)

Green solid, (68% yield), mp 229–230 °C; IR (KBr) νmax br. 3411 (2NH), 2919 (sp3 C-H), 1552 cm−1; 1H-NMR (DMSO-d6) δ 2.25 (s, 3H, CH3), 2.35 (s, 3H, CH3), 2.50 (s, 3H, CH3), 3.26 (s, 3H, CH3), 6.94 (d, J = 7 Hz, 2H, Ar-H), 7.07 (s, 1H, thiazole-H), 7.76 (d, J = 7 Hz, 2H, Ar-H), 8.50 (s, 1H, NH), 10.21 (s, 1H, NH); MS m/z (%) 357 (M+, 35), 346 (53), 324 (100), 298 (60), 270 (45), 229 (34), 174 (68), 145 (44), 135 (81), 115 (50), 65 (56). Anal. Calcd. for C17H19N5S2 (357.49): C, 57.12; H, 5.36; N, 19.59. Found: C, 57.30; H, 5.33; N, 19.46%.

3.3.8. 2-(2-(1-(4-Methoxyphenyl)ethylidene)hydrazineyl)-N,4′-dimethyl-[4,5′-bithiazol]-2′-amine (19f)

Green solid, (75% yield), mp 195–197 °C; IR (KBr) νmax 3386, 3265 (2NH), 2926 (sp3 C-H), 1597 (C=N) cm−1; 1H-NMR (DMSO-d6) δ 2.00 (s, 3H, CH3), 2.51 (s, 3H, CH3), 2.80 (s, 3H, CH3), 3.86 (s, 3H, OCH3), 7.30 (s, 1H, thiazole-H), 7.44 (d, J = 7 Hz, 2H, Ar-H), 7.57 (d, J = 7 Hz, 2H, Ar-H), 8.29 (s, 1H, NH), 10.39 (s, 1H, NH); MS m/z (%) 373 (M+, 24), 369 (52), 346 (100), 332 (55), 284 (24), 270 (63), 250 (34), 177 (36), 123 (37), 111 (63), 76 (38). Anal. Calcd. for C17H19N5OS2 (373.49): C, 54.67; H, 5.13; N, 18.75. Found: C, 54.76; H, 5.24; N, 18.65%.

3.3.9. 2-(2-(1-(5-Imino-4-(p-tolyl)-4,5-dihydro-1,3,4-thiadiazol-2-yl)ethylidene)hydrazineyl)-N,4′-dimethyl-[4,5′-bithiazol]-2′-amine (21a)

Green solid, (68% yield), mp 270–271 °C; IR (KBr) νmax br. 3423 (3NH), 2927 (sp3 C-H), 1590 (C=N) cm−1; 1H-NMR (DMSO-d6) δ 2.34 (s, 3H, CH3), 2.39 (s, 3H, CH3), 2.51 (s, 3H, CH3), 3.35 (s, 3H, CH3), 6.69–8.08 (m, 6H, Ar-H, thiazole-H, NH), 9.39 (s, 1H, NH), 10.91 (s, 1H, NH); MS m/z (%) 456 (M+, 34), 420 (24), 367 (24), 267 (26), 249 (52), 200 (44), 139 (33), 104 (21), 85 (60), 76 (29). Anal. Calcd. for C19H20N8S3 (456.61): C, 49.98; H, 4.42; N, 24.54. Found: C, 50.11; H, 4.27; N, 24.35%.

3.3.10. 2-(2-(1-(4-(4-Chlorophenyl)-5-imino-4,5-dihydro-1,3,4-thiadiazol-2-yl)ethylidene)-hydrazineyl)-N,4′-dimethyl-[4,5′-bithiazol]-2′-amine (21b)

Green solid, (65% yield), mp 278–280 °C; IR (KBr) νmax br. 3425 (3NH), 2991 (sp3 C-H), 1621 (C=N) cm−1; 1H-NMR (DMSO-d6) δ 1.92 (s, 3H, CH3), 2.41 (s, 3H, CH3), 2.68 (s, 3H, CH3), 7.50–8.11 (m, 6H, Ar-H, thiazole-H, NH), 8.66 (s, 1H, NH), 10.92 (s, 1H, NH); MS m/z (%) 479 (M++2, 34), 477 (M+, 73), 461 (41), 382 (33), 313 (15), 222 (26), 202 (36), 111 (15), 108 (32), 96 (100). Anal. Calcd. for C18H17ClN8S3 (477.02): C, 45.32; H, 3.59; N, 23.49. Found: C, 45.43; H, 3.41; N, 23.28%.

3.3.11. 3-(2-(4′-Methyl-2′-(methylamino)-[4,5′-bithiazol]-2-yl)hydrazineylidene)indolin-2-one (24)

Brown solid, (79% yield), mp 210–212 °C; IR (KBr) νmax 3419, 3262 (3NH), 1650 (C=O), 1600 (C=N) cm−1; 1H-NMR (DMSO-d6) δ 2.51 (s, 3H, CH3), 3.39 (s, 3H, CH3), 6.92 (d, J = 7.8 Hz, 1H, Ar-H), 7.07 (t, J = 7.45 Hz, 1H, Ar-H), 7.33 (t, J = 7.5 Hz, 1H, Ar-H), 7.65 (d, J = 7.44 Hz, 1H, Ar-H), 8.68 (s, 1H, thiazole-H), 9.03 (s, 1H, NH), 11.21 (s, 1H, NH), 12.48 (s, 1H. NH); MS m/z (%) 370 (M+, 29), 356 (50), 340 (32), 244 (45), 337 (50), 305 (40), 297 (63), 282 (25), 264 (58), 224 (32), 211 (44), 190 (100), 87 (44), 82 (19), 77 (32). Anal. Calcd. for C16H14N6OS2 (370.45): C, 51.88; H, 3.81; N, 22.69. Found: C, 52.02; H, 3.65; N, 22.53%.

3.3.12. 2,2′′-((1H-Indene-1,3(2H)-diylidene)bis(hydrazin-1-yl-2-ylidene))bis(N,4′-dimethyl-[4,5′-bithiazol]-2′-amine) (25)

Brown solid, (72% yield), mp 216–217 °C; IR (KBr) νmax 3415, 3240 (2NH), 2937 (sp3 C-H), 1575 (C=N) cm−1; 1H-NMR (DMSO-d6) δ 2.51 (s, 6H, 2CH3), 3.38 (s, 6H, 2CH3), 3.83 (s, 2H, CH2), 7.51–8.03 (m, 4H, Ar-H), 8.13(s, 2H, thiazole-H), 8.40 (s, 2H, 2NH), 10.02 (s, 2H, 2NH); MS m/z (%) 593 (M++1, 11), 567 (14), 548 (23), 531 (20), 510 (14), 439 (20), 404 (20), 360 (100), 352 (15), 276 (31), 226 (11), 211 (13), 200 (58). Anal. Calcd. for C25H24N10S4 (592.78): C, 50.66; H, 4.08; N, 23.63. Found: C, 50.76; H, 4.14; N, 23.58%.

3.4. Antimicrobial Screening

The starting α-bromoketone derivative 2 and the new thiazole compounds 6–8, 12–14, 17a,b, 19a, 19c–f, 21a,b, 24 and 25 were assayed in vitro for their antimicrobial activity against two fungal species, namely Aspergillus niger, Geotricum candidum, four Gram-positive bacteria: Staphylococcus aureus, Staphylococcus epidermidis, Bacillis subtilis, Streptococcus pyogenes, and four Gram-negative bacteria: Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Salmonella typhimurium using the known the agar diffusion procedure [36]. Firstly, the microorganisms were screened separately versus the activity of the solutions of each compound (30 μg/mL) and using the IZD diameter of the mm/mg sample as a measure of antimicrobial activity. The microorganisms were spread uniformly using a sterile cotton swab on a fresh Petri dish filled with agar and nutritient agar. One hundred μL of each sample was added to each well (10 mm diameter holes cut into the agar gel, 20 mm apart from each other). Petri dishes were incubated at 36 °C for bacteria and at 28 °C for fungus and inhibition zones were measured after 24 h of incubation. Inhibition of growth of bacteria and fungi was measured as IZD in mm. Each test was repeated three times and the average value is recorded. The fungicide amphotericin and gentamicin and ampicillin were used as a reference to evaluate the efficacy of the tested compounds under the same conditions.

3.5. Conformational Study

The synthesis pathways were also confirmed based on structural configuration studies which were performed using the Gaussian 09 software [37]. To determine the most stable conformers (in gas phase), the DFT method was applied as B3LYP-FC, by using the 3-21G or 6-31G basis sets. Two significant files were extracted (log and chk), which feed the study of the essential parameters, for confirmation. All optimized conformers were visualized using the Gauss-View program screen [38], to obtain frontier energy gaps and electrostatic potential maps. Other physical parameters were computed by using standard equations [39,40].

3.6. Molecular Docking Study

Through the MOE module (v. 2015), the molecular docking process was implemented forselected compounds against three microorganisms. Regarding the tested inhibitors, the selection aimd to cover all the various synthesis pathways, to give a broad view about their interactions with pathogen proteins. Regarding the selected pathogens, Aspergillus niger, Bacillis subtilis and Escherichia coli, which cover fungi and bacteria, were selected, which will simulate the intended screening in vitro study. 3k4p, 1ydo and 1ecl, were the co-crystalline structures as PDB files, which are attributed to the reported microorganisms, respectively. This introductory study may strengthen the experimental screening, which will be displayed later. Firstly the docked synthesis must be configured by the addition of hydrogen atoms, after removing water molecules around the skeletons. Then the potential energy must be fixed after displaying the atomic charges and other important parameters adapted by the MMFF94x force field. After that, the oriented compounds must be saved as MDB format, to be ready for the docking process. The PDB files of co-crystallized proteins are configured by addition of hydrogen, choosing the receptor and generating the α-site spheres in the site finder [41]. The docking inhibitors will attack the protein-surfaces in its interior-grooves, after 30 trials, till the most stable docking complexes are reached. The scoring energies, which were the mean values of trials using the London dG scoring function, were upgraded by two unrelated-refinements by the triangular Matcher methods. The interacting complexes as well as electrostatic maps for the interacting surfaces were extracted, in addition to essential interaction parameters. The grade of inhibition was judged based on the extracted parameters such as ligand, receptor backbones (amino acids), interaction type, bond lengths, internal and scoring energies. The bond lengths must be verified, are were limited to ≤ 3.5 Å

4. Conclusions

A main and growing health problem around the world is microbial resistance to existing treatments. Several studies have been conducted aiming to synthesize thiazole derivatives with excellent antimicrobial activity. In this context we focused on the synthesis for a new series of thiazole derivatives with varying substituents at position-5. The atomic assembly and the mechanistic pathway for all products have been investigated and proved based on our spectral and conformational studies. Antimicrobial results for the starting material (α-bromoketone) and the products indicated that the antimicrobial activity of some new synthetic products is more efficient than that of the starting material itself. This activity of the derivatives was somewhat improved to exceed the activity of standard drugs.

Supplementary Materials

The following are available online.

Author Contributions

Conceptualization, I.A., N.E. and T.A.F.; methodology, T.A.F.; software, N.E.; validation, I.A., N.E. and T.A.F.; formal analysis, I.A., N.E. and T.A.F.; investigation, I.A., N.E. and T.A.F.; resources, I.A., N.E. and T.A.F.; data curation, I.A., N.E. and T.A.F.; Writing—Original Draft preparation, I.A., N.E. and T.A.F.; Writing—Review and Editing, I.A., N.E. and T.A.F.; supervision, I.A., N.E. and T.A.F.; project administration, I.A.; funding acquisition, I.A.

Funding

This research was funded by Deanship of Scientific Research at Umm Al-Qura University, grant number 17-SCI-1-01-0004.

Acknowledgments

Ismail Althagafi and co-authors would like to thank Deanship of Scientific Research at Umm Al-Qura University (project ID: 17-SCI-1-01-0004) for the financial support to this research extracted from the project.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Shirai, A.; Fumoto, Y.; Shouno, T.; Maseda, H.; Omasa, T. Synthesis and biological activity of thiazolyl-acetic acid derivatives as possible antimicrobial agents. Biocontrol Sci. 2013, 18, 59–73. [Google Scholar] [CrossRef] [PubMed]
  2. Prajapati, N.P.; Patel, K.D.; Vekariya, R.H.; Patel, H.D.; Rajani, D.P. Thiazole fused thiosemicarbazones: Microwave-assisted synthesis, biological evaluation and molecular docking study. J. Mol. Str. 2019, 1179, 401–410. [Google Scholar] [CrossRef]
  3. Lino, C.I.; de Souza, I.G.; Borelli, B.M.; Matos, T.T.S.; Teixeira, I.N.S.; Ramos, J.P.; de Souza Fagundes, E.M.; Fernandes, P.O.; Maltarollo, V.G.; Johann, S.; et al. Synthesis, molecular modeling studies and evaluation of antifungal activity of a novel series of thiazole derivatives. Eur. J. Med. Chem. 2018, 151, 248–260. [Google Scholar] [CrossRef] [PubMed]
  4. Reddy, G.M.; Garcia, J.R.; Reddy, V.H.; de Andrade, A.M.; Camilo, A., Jr.; Ribeiro, R.A.P.; de Lazaro, S.R. Synthesis, antimicrobial activity and advances in structure-activity relationships (SARs) of novel tri-substituted thiazole derivatives. Eur. J. Med. Chem. 2016, 123, 508–513. [Google Scholar] [CrossRef] [PubMed]
  5. Sinha, S.; Doble, M.; Manju, S.L. Design, synthesis and identification of novel substituted 2-amino thiazole analogues as potential anti-inflammatory agents targeting 5-lipoxygenase. Eur. J. Med. Chem. 2018, 158, 34–50. [Google Scholar] [CrossRef] [PubMed]
  6. Kamble, R.D.; Meshram, R.J.; Hese, S.V.; More, R.A.; Kamble, S.S.; Gacche, R.N.; Dawane, B.S. Synthesis and in silico investigation of thiazoles bearing pyrazoles derivatives as anti-inflammatory agents. Comput. Biol. Chem. 2016, 61, 86–96. [Google Scholar] [CrossRef] [PubMed]
  7. Pember, S.O.; Mejia, G.L.; Price, T.J.; Pasteris, R.J. Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties. Bioorg. Med. Chem. Lett. 2016, 26, 2965–2973. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Wang, Y.; Wu, C.; Zhang, Q.; Shan, Y.; Gu, W.; Wang, S. Design, synthesis and biological evaluation of novel β-pinene-based thiazole derivatives as potential anticancer agents via mitochondrial-mediated apoptosis pathway. Bioorg. Chem. 2019, 84, 468–477. [Google Scholar] [CrossRef]
  9. Santana, T.I.; Barbosa, M.O.; Gomes, P.A.T.M.; Cruz, A.C.N.; Silva, T.G.; LimaLeite, A.C. Synthesis, anticancer activity and mechanism of action of new thiazole derivatives. Eur. J. Med. Chem. 2018, 144, 874–886. [Google Scholar] [CrossRef] [PubMed]
  10. Cushman, M.S.; Seleem, M.; Mayhoub, A.S. Antimicrobial Substituted Thiazoles and Methods of Use. United States Patent Patent No.: US 9, 801, 861 B2, 2017. [Google Scholar]
  11. Leoni, A.; Locatelli, A.; Morigi, R.; Rambaldi, M. Novel thiazole derivatives: A patent review (2008–2012; Part 1). Expert Opin. Ther. Patents 2014, 24, 201–216. [Google Scholar] [CrossRef] [PubMed]
  12. Muhammad, Z.A.; Masaret, G.S.; Amin, M.M.; Abdallah, M.A.; Farghaly, T.A. Anti-inflammatory, analgesic and anti-ulcerogenic activities of novel bis-thiadiazoles, bis-thiazoles and bis-formazanes. Med. Chem. 2017, 13, 226–238. [Google Scholar] [CrossRef] [PubMed]
  13. Gong, C.; Gao, A.-H.; Zhang, Y.-M.; Su, M.-B.; Chen, F.; Sheng, L.; Zhou, Y.-B.; Li, J.-Y.; Li, J.; Nan, F.-J. Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy. Eur. J. Med. Chem. 2016, 112, 81–90. [Google Scholar] [CrossRef] [PubMed]
  14. Fairhurst, R.A.; Imbach-Weese, P.; Gerspacher, M.; Caravatti, G.; Furet, P.; Zoller, T.; Christine, F.; Haasen, D.; Trappe, J.; Guthy, D.A.; et al. Identification and optimisation of a 4′,5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitors. Bioorg. Med. Chem. Lett. 2015, 25, 3569–3574. [Google Scholar] [CrossRef] [PubMed]
  15. Althagafi, I.I.; Abouzied, A.S.; Farghaly, T.A.; Al-Qurashi, N.T.; Alfaifi, M.Y.; Shaaban, M.R.; Abdel Azizd, M.R. Novel Nano-sized bis-indoline Derivatives as Antitumor Agents. J. Heterocyclic Chem. 2019, 56, 391–399. [Google Scholar] [CrossRef]
  16. Turan-Zitouni, G.; Altıntop, M.D.; Özdemir, A.; Kaplancıklı, Z.A.; Çiftçi, G.A.; Temel, H.E. Synthesis and evaluation of bis-thiazole derivatives as new anticancer agents. Eur. J. Med. Chem. 2016, 288–294. [Google Scholar] [CrossRef]
  17. Álvarez, G.; Martínez, J.; Varela, J.; Birriel, E.; Cruces, E.; Gabay, M.; Leal, S.M.; Escobar, P.; Aguirre-López, B.; Cabrera, N.; et al. Development of bis-thiazoles as inhibitors of triosephosphate isomerase from Trypanosoma cruzi. Identification of new non-mutagenic agents that are active in vivo Panel. Eur. J. Med. Chem. 2015, 100, 246–256. [Google Scholar] [CrossRef] [PubMed]
  18. Alsharekh, M.M.; Althagafi, I.I.; Shaaban, M.R.; Farghaly, T.A. Microwave assisted and thermal synthesis of nanosized thiazolyl-phenothiazine derivatives and their biological activities. Res. Chem. Intermed. 2019, 45, 127–154. [Google Scholar] [CrossRef]
  19. Althagafi, I.; El-Metwally, N.M.; Elghalban, M.; Farghaly, T.A.; Khedr, A.M. Synthesis of Pyrazolone Derivatives and their Nanometer Ag(I)complexes, Physicochemical, DNA binding, Anti-Tumor and Theoretical Implementations. Bioinorg. Chem. Appl. 2018, 2018, 1–15. [Google Scholar] [CrossRef]
  20. Dawood, D.H.; Abbas, E.M.H.; Farghaly, T.A.; Ali, M.M.; Ibrahim, M.F. ZnO Nanoparticles catalyst in Synthesis of Bioactive Fused Pyrimidines as Anti-breast Cancer Agents Targeting VEGFR-2. Med. Chem. 2019, 15, 277–286. [Google Scholar] [CrossRef]
  21. Farghaly, T.A.; Abdel Hafez, N.A.; Ragab, E.A.; Awad, H.M.; Abdalla, M.M. Synthesis, anti-HCV, antioxidant, and peroxynitrite inhibitory activity of fused benzosuberone derivatives. Eur. J. Med. Chem. 2010, 45, 492–500. [Google Scholar] [CrossRef]
  22. Farghaly, T.A.; Abdallah, M.A.; Masaret, G.S.; Muhammad, Z.A. New and efficient approach for synthesis of novel bioactive [1,3,4]thiadiazoles incorporated with 1,3-thiazole moiety. Eur. J. Med. Chem. 2015, 320–333. [Google Scholar] [CrossRef] [PubMed]
  23. Riyadh, S.M.; Farghaly, T.A.; Abdallah, M.A.; Abdalla, M.M.; Abd El-Aziz, M.R. New pyrazoles incorporating pyrazolylpyrazole moiety: Synthesis, anti-HCV and antitumor activity. Eur. J. Med. Chem. 2010, 45, 1042–1050. [Google Scholar] [CrossRef]
  24. Al-Fahemi, J.H.; Saad, F.A.; El-Metwaly, N.M.; Farghaly, T.A.; Elghalban, M.G.; Saleh, K.A.; Al-Hazmi, G.A. Synthesis of Co(II), Cu(II), Hg(II), UO2(II) and Pb(II) binuclear nanometric complexes from multi-donor ligand: Spectral, modeling, quantitative structure – activity relationship, docking and antitumor studies. Appl Organometal Chem. 2017, 31, 3787. [Google Scholar] [CrossRef]
  25. Mohamed, S.F.; Abbas, E.M.; Khalaf, H.H.S.; Farghaly, T.A.; Abd El-Shafy, D.N. Triazolopyrimidines and Thiazolopyrimidines: Synthesis, Anti-HSV-1, Cytotoxicity and Mechanism of action. Med. Chem. 2018, 18, 794–802. [Google Scholar] [CrossRef] [PubMed]
  26. Hiebel, M.-A.; Fall, Y.; Scherrmann, M.-C.; Berteina-Raboin, S. Straightforward Synthesis of Various 2,3-Diarylimidazo[1,2-a]pyridines in PEG400 Medium through One-Pot Condensation and C–H Arylation. Eur. J. Org. Chem. 2014, 2014, 4643–4650. [Google Scholar] [CrossRef]
  27. Ramprasad, J.; Nayak, N.; Dalimba, U.; Yogeeswari, P.; Sriram, D.; Peethambar, S.K.; Achur, R.; Kumar, H.S.S. Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4] thiadiazole-benzimidazole derivatives. Eur. J. Med. Chem. 2015, 95, 49–63. [Google Scholar] [CrossRef]
  28. Shawali, A.S.; Abdalla, M.A.; Mosselhi, M.A.N.; Farghaly, T.A. A Facile one-pot regioselective synthesis of [1,2,4]triazolo[4,3-a]-5(1H)-pyrimidinones via tandem Japp-Klingemann, Smiles rearrangement, and cyclization reactions. Heteroatom Chem. 2002, 13, 136–140. [Google Scholar] [CrossRef]
  29. Chikate, R.C.; Padhye, S.B. Transition metal quinone–thiosemicarbazone complexes 2: Magnetism, ESR and redox behavior of iron (II), iron (III), cobalt (II) and copper (II) complexes of 2-thiosemicarbazido-1,4-naphthoquinone. Polyhedron 2005, 24, 1689–1700. [Google Scholar] [CrossRef]
  30. Sagdinc, S.; Köksoy, B.; Andemirli, K.F.; Bayari, S.H. Theoretical and spectroscopic studies of 5-fluoro-isatin-3-(N-benzylthiosemicarbazone) and its zinc(II) complex. J. Mol. Struct. 2009, 917, 63–70. [Google Scholar] [CrossRef]
  31. Fleming, I. Frontier Orbital’s and Organic Chemical Reactions; Wiley: London, UK, 1976. [Google Scholar]
  32. Tripathi, S.K.; Muttineni, R.; Singh, S.K. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors. J. Theor. Biol. 2013, 334, 87–100. [Google Scholar] [CrossRef]
  33. Gross, S.; Rahal, R.; Stransky, N.; Lengauer, C.; Hoeflich, K.P. Targeting cancer with kinase inhibitors. J. Clin. Investig. 2015, 125, 1780–1789. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Fadda, A.A.; Abdel-Latif, E.; Fekri, A.; Mostafa, A.R. Synthesis and Docking Studies of Some 1,2,3-Benzotriazine-4-one Derivatives as Potential Anticancer Agents. J. Heterocyclic Chem. 2019, 56, 804–814. [Google Scholar] [CrossRef]
  35. Abd El-Karima, S.S.; Anwara, M.M.; Syama, Y.M.; Naelb, M.A.; Alia, H.F.; Motaleb, M.A. Rational design and synthesis of new tetralin-sulfonamide derivatives as potent anti-diabetics and DPP-4 inhibitors: 2D & 3D QSAR, in vivo radiolabeling and bio distribution studies. Bioorg. Chem. 2018, 81, 481–493. [Google Scholar]
  36. Cruickshank, R.; Duguid, J.P.; Marion, B.P.; Swain, R.H.A. Medicinal Microbiology, 12th ed.; Churchill Livingstone: London, UK, 1975; Volume II, pp. 196–202. [Google Scholar]
  37. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Scalmani, G.; Barone, V.; Petersson, G.A.; Nakatsuji, H.; et al. Gaussian 09; Revision D; Gaussian, Inc.: Wallingford, CT, USA, 2010. [Google Scholar]
  38. Dennington, R.; Keith, T.; Millam, J. Gauss View, Version 4.1.2; SemichemInc: Shawnee Mission, KS, USA, 2007. [Google Scholar]
  39. El-Ayaan, U.; El-Metwally, N.M.; Youssef, M.M.; El Bialy, S.A.A. Perchlorate mixed–ligand copper(II) complexes of β-diketone and ethylene diamine derivatives: Thermal, spectroscopic and biochemical studies. Spectrochim. Acta Part A 2007, 68, 1278–1286. [Google Scholar] [CrossRef]
  40. Ray, R.K.; Kauffman, G.R. EPR Spectra and covalency of bis(amidinourea/O-alkyl-1-amidinourea)copper(II) complexes Part II.Properties of the CuN42− chromophore. Inorg. Chem. Acta 1990, 173, 207–214. [Google Scholar] [CrossRef]
  41. Mashat, K.H.; Babgi, B.A.; Hussien, M.A. Synthesis, structures, DNA-binding and anticancer activities of some copper(I)-phosphine complexes. Polyhedron 2019, 158, 164–172. [Google Scholar] [CrossRef]
Sample Availability: Samples of the compounds 6–8, 12–14, 17a,b, 19a–f, 21a,b, 24 and 25 are available from the authors.
Molecules 24 01741 g001 550
Figure 1. Natural and available marketing drugs containing thiazole rings.
Figure 1. Natural and available marketing drugs containing thiazole rings.
Molecules 24 01741 g001
Molecules 24 01741 sch001 550
Scheme 1. Synthesis of thiazole derivatives 6–8.
Scheme 1. Synthesis of thiazole derivatives 6–8.
Molecules 24 01741 sch001
Molecules 24 01741 sch002 550
Scheme 2. The mechanism of the formation of isomer 6A.
Scheme 2. The mechanism of the formation of isomer 6A.
Molecules 24 01741 sch002
Molecules 24 01741 sch003 550
Scheme 3. Synthesis of compounds 12–14.
Scheme 3. Synthesis of compounds 12–14.
Molecules 24 01741 sch003
Molecules 24 01741 sch004 550
Scheme 4. Reaction of α-bromoketone derivative 2 with pyrimidine thione 15a,b.
Scheme 4. Reaction of α-bromoketone derivative 2 with pyrimidine thione 15a,b.
Molecules 24 01741 sch004
Molecules 24 01741 g002 550
Figure 2. 1H-NMR spectrum of compound 17a which exists in the tautomeric form C.
Figure 2. 1H-NMR spectrum of compound 17a which exists in the tautomeric form C.
Molecules 24 01741 g002
Molecules 24 01741 sch005 550
Scheme 5. Synthesis of compounds 19a–f.
Scheme 5. Synthesis of compounds 19a–f.
Molecules 24 01741 sch005
Molecules 24 01741 sch006 550
Scheme 6. Synthesis of compounds 21a,b.
Scheme 6. Synthesis of compounds 21a,b.
Molecules 24 01741 sch006
Molecules 24 01741 sch007 550
Scheme 7. Synthesis of compounds 24 and 25.
Scheme 7. Synthesis of compounds 24 and 25.
Molecules 24 01741 sch007
Molecules 24 01741 g003 550
Figure 3. Mass fragmentations for compound 19b.
Figure 3. Mass fragmentations for compound 19b.
Molecules 24 01741 g003
Molecules 24 01741 g004 550
Figure 4. Electrostatic potential of selected reaction determining compounds.
Figure 4. Electrostatic potential of selected reaction determining compounds.
Molecules 24 01741 g004
Molecules 24 01741 g005a 550Molecules 24 01741 g005b 550
Figure 5. Best docking interaction (A) and surfaces maps (B) of selected compounds.
Figure 5. Best docking interaction (A) and surfaces maps (B) of selected compounds.
Molecules 24 01741 g005aMolecules 24 01741 g005b
Table
Table 1. Calculated physical parameters for all suggested conformers.
Table 1. Calculated physical parameters for all suggested conformers.
ConformersEH (eV)EL (eV)EH − ELEL − EHx(eV)µ(eV)η(eV)S(eV-1)ω(eV)σ(eV)D(Debye)E (a. u.)
3A−0.20464−0.00446−0.20020.200180.10455−0.104550.100090.0500450.0546049.9910080932.4276−621.17858
3B−0.20794−0.01183−0.19610.19611------------------------------------2.7935−621.14667
6A−0.2024−0.07871−0.12370.123690.140555−0.140560.0618450.0309230.1597216.16945596.0085−1394.9439
6B−0.17951−0.07617−0.10330.10334------------------------------------10.9130−1394.4678
7A−0.19955−0.0716−0.1280.127950.135575−0.135580.0639750.0319880.14365415.63110596.0625−1547.7641
7B−0.14724−0.09765−0.04960.04959------------------------------------13.5781−1547.1272
8A−0.1861−0.06861−0.11750.117490.127355−0.127360.0587450.0293730.13804817.022725347.8499−1456.1575
8B−0.18661−0.0561−0.13050.13051------------------------------------6.2621−1456.0837
12A−0.20807−0.08663−0.12140.121440.14735−0.147350.060720.030360.17878816.4690382112.6129−1085.6105
12B−0.21277−0.10635−0.10640.10642------------------------------------10.4034−1085.4218
13−0.19029−0.09108−0.09920.099210.140685−0.140690.0496050.0248030.19949920.1592581410.1242−1206.5564
14−0.2007−0.06744−0.13330.133260.13407−0.134070.066630.0333150.13488515.008254548.2866−1069.7172
16−0.21735−0.06425−0.15310.15310.1408−0.14080.076550.0382750.12948813.063357285.5798−1813.6492
17A (R = Ph)−0.19633−0.06873−0.12760.12760.13253−0.132530.06380.03190.1376515.673981193.9127−1737.5001
17B (R = Ph)−0.16956−0.10827−0.06130.06129------------------------------------15.6710−1728.4984
19a−0.22389−0.12297−0.10090.100920.17343−0.173430.050460.025230.29803819.817677372.9358−1679.9270
21 (X = H)−0.21284−0.12465−0.08820.088190.168745−0.168750.0440950.0220480.32288122.67830826.1375−2315.6659
24−0.17775−0.09774−0.080.080010.137745−0.137750.0400050.0200030.23714124.996875392.8473−1817.4536
25−0.25151−0.01744−0.23410.234070.134475−0.134480.1170350.0585180.0772578.5444525146.9055−3093.4323
Table
Table 2. The energy score and binding data for all compounds against selected proteins.
Table 2. The energy score and binding data for all compounds against selected proteins.
CompoundProteinLigandReceptorInteractionDistanceE (Kcal/mol)S (Energy Score)
143k4pS 4OGSERH-donor3.75−0.5−5.1153
99(A)
N 13OGSERH-donor3.09−1.6
99(A)
5-ringCBTHRpi-H4.41−0.5
248(A)
1ydo-------------------------−4.5481
1eclN 13OHOHH-donor3.33−1.7−4.3294
744(A)
17a3k4pS 4OE1GLNH-donor3.18−0.7−5.2078
13(B)
6-ringCBGLNpi-H4.00−0.5
16(B)
6-ringCACYSpi-H4.35−0.8
17(B)
1ydo5-ringCBLYSpi-H4.00−1.1−7.0064
297(B)
1ecl-------------------------−4.9748
19f3k4pS 1OD1ASNH-donor3.88−1.4−5.8156
36(A)
N 6OE2GLUH-donor2.99−4.6
43(A)
S 20OALAH-donor3.43−1.3
35(A)
N 22OSERH-donor3.01−1.7
38(A)
5-ringCASERpi-H4.10−0.5
41(A)
1ydo5-ring5-ringTRPpi-pi3.88−0.0−6.2008
55(A)
5-ring6-ringTRPpi-pi4.00−0.0
55(A)
5-ring6-ringTRPpi-pi3.8−0.0
55(A)
1eclS 20OD2ASPH-donor3.52−2.9−5.0501
62(A)
N 7OHOHH-acceptor3.03−0.9
1030(A)
N 18OHOHH-acceptor3.60−1.2
1039(A)
243k4pN 7OE1GLUH-donor3.2−0.7−5.3916
37(A)
N 11OGLUH-donor3.49−0.7
37(A)
S 17OGLUH-donor4.21−0.9
37(A)
5-ringCGPROpi-H3.64−0.8
409(A)
1ydo5-ringCBLYSpi-H4.27−0.5−6.8467
297(B)
1eclS 22OD2ASPH-donor3.80−3.3−4.9736
506(A)
N 23OD2ASPH-donor3.05−4.0
506(A)
O 13NZLYSH-acceptor3.22−5.1
302(A)
5-ringOHOHpi-H3.63−1.2
661(A)
Table
Table 3. Preliminary anti-microbial activity for compounds 2, 6–8, 12.
Table 3. Preliminary anti-microbial activity for compounds 2, 6–8, 12.
Microorganism267812ST. (30 µg/mL)
Fungi Amphotericin B
Aspergillus niger18.8 ± 0.6319.3 ± 0.6318.4 ± 1.2019.2 ± 0.7223.3 ± 0.7223.3 ± 0.58
Geotricum candidum19.3 ± 0.5818.1 ± 0.5816.3 ± 0.6317.3 ± 0.7222.3 ± 1.2025.2 ± 0.72
G(+) Bacteria Ampicillin
Staphylococcus aureus17.6 ± 0.8519.3 ± 0.5821.1 ± 0.6313.5 ± 1.2020.1 ± 0.5823.7 ± 0.63
Staphylococcus epidermidis18.1 ± 1.2017.4 ± 0.5820.7 ± 0.7215.3 ± 0.4417.6 ± 0.7222.4 ± 0.3
Bacillis subtilis18.3 ± 0.6322.7 ± 1.2020.1 ± 0.5318.2 ± 0.5824.3 ± 0.5832.4 ± 1.20
Streptococcus pyogenesNANANANANA24.5 ± 0.63
G(−) Bacteria Gentamicin
Pseudomonas aeruginosaNANANANANA22.3 ± 0.58
Escherichia coli20.2 ± 0.5820.3 ± 0.6319.3 ± 1.2019.3 ± 0.6323.7 ± 0.72 25.4 ± 1.20
Klebsiella pneumoniae18.2 ± 1.2018.2 ± 0.5819.2 ± 1.2016.3 ± 0.6319.3 ± 0.6322.6 ± 0.63
Salmonella typhimurium17.5 ± 0.6320.4 ± 0.7218.4 ± 0.5819.3 ± 0.5821.6 ± 0.6323.3 ± 0.58
Molecules 24 01741 i002 The tested compound has activity similar to reference drug.
Table
Table 4. Preliminary anti-microbial activity for compounds 13, 14, 17a,b and 19a.
Table 4. Preliminary anti-microbial activity for compounds 13, 14, 17a,b and 19a.
Microorganism131417a17b19aST. (30 µg/mL)
Fungi Amphotericin B
Aspergillus niger21.2 ± 1.2025.4 ± 1.2024.3 ± 1.2023.1 ± 1.2025.0 ± 0.7223.3 ± 0.58
Geotricum candidum19.3 ± 0.8520.9 ± 0.7224.2 ± 1.2023.6 ± 1.2023.6 ± 0.6325.2 ± 0.72
G (+)Bacteria Ampicillin
Staphylococcus aureus16.8 ± 0.6324.3 ± 0.6323.6 ± 0.6322.4 ± 0.6323.8 ± 0.7223.7 ± 0.63
Staphylococcus epidermidis15.2 ± 0.5822.8 ± 0.5822.4 ± 0.7220.9 ± 0.7221.9 ± 0.7222.4 ± 0.3
Bacillis subtilis20.6 ± 0.5821.6 ± 0.5327.2 ± 0.6329.8 ± 0.6325.2 ± 0.6332.4 ± 1.20
Streptococcus pyogenesNANANANANA24.5 ± 0.63
G (−)Bacteria Gentamicin
Pseudomonas aeruginosaNANANANANA22.3 ± 0.58
Escherichia coli19.8 ± 1.2024.3 ± 1.2026.7 ± 1.2024.3 ± 1.2026.9 ± 1.20 25.4 ± 1.20
Klebsiella pneumoniae18.3 ± 0.5322.2 ± 0.4425.3 ± 1.2022.2 ± 1.2026.3 ± 1.2022.6 ± 0.63
Salmonella typhimurium20.1 ± 0.6321.1 ± 0.7226.3 ± 0.5824.8 ± 0.5822.2 ± 0.5823.3 ± 0.58
Molecules 24 01741 i001 The tested compound has activity exceed the reference drug.
Molecules 24 01741 i002 The tested compound has activity similar to reference drug.
Table
Table 5. Preliminary anti-microbial activity for compounds 19c–f and 21a.
Table 5. Preliminary anti-microbial activity for compounds 19c–f and 21a.
Microorganism19c19d19e19f21aST. (30 µg/mL)
Fungi Amphotericin B
Aspergillus niger21.8 ± 0.43 25.2 ± 2.1024.1 ± 0.5826.3 ± 0.6325.2 ± 2.1023.3 ± 0.58
Geotricum candidum21.4 ± 0.72 23.2 ± 2.1020.5 ± 0.5824.2 ± 0.6323.2 ± 2.1025.2 ± 0.72
G (+) Bacteria Ampicillin
Staphylococcus aureus20.3 ± 0.4322.1 ± 1.2022.4 ± 0.6322.7 ± 1.2024.1 ± 1.2023.7 ± 0.63
Staphylococcus epidermidis18.6 ± 0.5819.8 ± 0.6720.9 ± 0.7221.3 ± 0.5819.8 ± 0.6722.4 ± 0.3
Bacillis subtilis22.4 ± 1.5324.3 ± 0.5823.8 ± 0.6323.9 ± 0.7226.3 ± 0.5832.4 ± 1.20
Streptococcus pyogenesNANANANANA24.5 ± 0.63
G (−) Bacteria Gentamicin
Pseudomonas aeruginosaNANANANANA22.3 ± 0.58
Escherichia coli23.3 ± 0.5824.2 ± 0.5824.3 ± 1.2025.4 ± 1.2024.2 ± 0.5825.4 ± 1.20
Klebsiella pneumoniae20.4 ± 0.5321.3 ± 0.5822.5 ± 1.2023.1 ± 1.2021.3 ± 0.5822.6 ± 0.63
Salmonella typhimurium22.6 ± 0.6323.3 ± 1.2026.3 ± 0.5826.7 ± 0.7223.3 ± 1.2023.3 ± 0.58
Molecules 24 01741 i001 The tested compound has activity exceed the reference drug.
Molecules 24 01741 i002 The tested compound has activity similar to reference drug.
Table
Table 6. Preliminary anti-microbial activity for compounds 21b, 24 and 25.
Table 6. Preliminary anti-microbial activity for compounds 21b, 24 and 25.
Microorganism21b2425ST. (30 µg/mL)
Fungi Amphotericin B
Aspergillus niger19.2 ± 0.72 26.3 ± 0.6323.3 ± 0.7223.3 ± 0.58
Geotricum candidum16.3 ± 0.72 24.2 ± 0.6321.4 ± 0.7225.2 ± 0.72
G(+) Bacteria Ampicillin
Staphylococcus aureus17.5 ± 1.2022.7 ± 1.2020.3 ± 0.4323.7 ± 0.63
Staphylococcus epidermidis21.3 ± 0.4421.3 ± 0.5819.8 ± 0.5822.4 ± 0.3
Bacillis subtilis18.2 ± 0.5828.9 ± 0.7225.4 ± 0.5332.4 ± 1.20
Streptococcus pyogenesNANANA24.5 ± 0.63
G (−) Bacteria Gentamicin
Pseudomonas aeruginosaNANANA22.3 ± 0.58
Escherichia coli20.3 ± 0.6325.6 ± 1.2024.3 ± 0.53 25.4 ± 1.20
Klebsiella pneumoniae21.3 ± 0.6323.8 ± 1.2021.5 ± 0.5322.6 ± 0.63
Salmonella typhimurium19.9 ± 0.5825.4 ± 0.7222.6 ± 0.6323.3 ± 0.58
Molecules 24 01741 i001 The tested compound has activity exceed the reference drug.
Molecules 24 01741 i002 The tested compound has activity similar to reference drug.
Table
Table 7. Minimum inhibitory concentration of compounds 7, 13, 17a,b, 19c and 21b (µg/mL).
Table 7. Minimum inhibitory concentration of compounds 7, 13, 17a,b, 19c and 21b (µg/mL).
Microorganism71317a17b19c21bST. (30 µg/mL)
Fungi Amphotericin B
Aspergillus niger0.983.90.980.980.9831.250.98
Geotricum candidum0.981.950.490.983.962.50.49
G (+) Bacteria Ampicillin
Staphylococcus aureus1.9531.250.980.983.962.50.98
Staphylococcus epidermidis3.931.251.957.817.811.951.95
Bacillis subtilis0.9862.53.90.4931.2562.50.49
Streptococcus pyogenesNANANANANANA0.49
G (−) Bacteria Gentamicin
Pseudomonas aeruginosaNANANANANANA1.95
Escherichia coli0.987.810.490.491.957.810.49
Klebsiella pneumoniae1.953.90.981.950.983.90.98
Salmonella typhimurium0.490.491.950.981.953.90.98

Share and Cite

MDPI and ACS Style

Althagafi, I.; El-Metwaly, N.; Farghaly, T.A. New Series of Thiazole Derivatives: Synthesis, Structural Elucidation, Antimicrobial Activity, Molecular Modeling and MOE Docking. Molecules 2019, 24, 1741. https://doi.org/10.3390/molecules24091741

AMA Style

Althagafi I, El-Metwaly N, Farghaly TA. New Series of Thiazole Derivatives: Synthesis, Structural Elucidation, Antimicrobial Activity, Molecular Modeling and MOE Docking. Molecules. 2019; 24(9):1741. https://doi.org/10.3390/molecules24091741

Chicago/Turabian Style

Althagafi, Ismail, Nashwa El-Metwaly, and Thoraya A. Farghaly. 2019. "New Series of Thiazole Derivatives: Synthesis, Structural Elucidation, Antimicrobial Activity, Molecular Modeling and MOE Docking" Molecules 24, no. 9: 1741. https://doi.org/10.3390/molecules24091741

Article Metrics

Back to TopTop